|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||33.26 - 33.49|
|52-week range||29.83 - 35.38|
|PE ratio (TTM)||28.08|
|Earnings date||30 Oct 2017 - 3 Nov 2017|
|Dividend & yield||1.28 (3.83%)|
|1y target est||37.45|
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
The president may want to check his facts on Merck, which he accused of "taking jobs out of the U.S."
Apart from Pfizer’s (PFE) product developments, let's take a look at some recent pipeline and corporate developments.